A perioperative study in low-grade glioma with an IDH1 mutation suggested brain penetrance and robust biomarker suppression with treatment of single agent vorasidenib or ivosidenib.
Active choice intervention in the electronic health record directed to medical assistants was associated with a significant increase in clinician ordering of breast and colorectal cancer screening tests.
